Market closed · Next open: Friday 9:30 AM ET
Last update: Sep 17, 2026, 6:08 PM ET
Pfizer Inc.
$27.64 0.64% today
Market Closed

Why Pfizer Inc. (PFE) stock moved

Updated Sep 18, 2026

Pfizer Inc. (PFE) shares rose 0.6% to $27.64 as of September 18, 2026, a slight gain from the prior close of $27.46. BestStocks flagged the session as a major change for PFE. No single company-specific catalyst was confirmed, so the move reads as a sector-wide move. Below, we break down what changed for PFE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

PFE climbed 0.6% to $27.64

Pfizer Inc. (PFE) moved +0.80% from $28.79 to $29.02 on 2026-09-02. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move aligns with a sector-wide rally: six pharma peers (AMGN +3.01%, ABBV +2.06%, MRK +2.69%, UNH +2.63%, and others) advanced simultaneously, suggesting broad sector momentum rather than a PFE-specific event. Pfizer earnings are scheduled for 2026-11-03, with consensus EPS estimate of $0.79.

This summary describes the catalyst and move as first detected on Sep 2, 2026, 4:40 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Sector-Wide MoveWeak confidence
Rel. volume
0.7×
Below Avg
Vs peers
Top 5 of 7 peers
In Line With Peers
Market cap
$157.5B
New York Stock Exchange
Analyst target
$29
+3.1% vs price
Price chart
Aug 18 – Sep 18
VVEVVE$27$28$29Aug 18Aug 26Sep 2Sep 11Sep 18
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Pfizer Inc. investors

For Pfizer Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.6% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in PFE's fundamentals. Wall Street's consensus price target sits at $28.50, implying +3.1% upside from $27.64. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality weak (29/100). With earnings roughly 46 days out, the next report is the most likely near-term test of the move.

PFE price reaction

PFE last traded at $27.64, up $0.18 (+0.64%) from the previous close of $27.46. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +1.1% over the same stretch, leaving PFE essentially in line with peers. Over the past month the stock has ranged between $27.25 and $29.02, and it currently sits about 22% of the way up that band.

Bullish and bearish analyst opinions on Pfizer Inc. (PFE)

The consensus analyst price target on Pfizer Inc. (PFE) is $28.50, 3.1% above the recent $27.64. Over the past 90 days analysts logged 0 upgrades, 7 maintains, and 1 downgrade. Here is how the bullish and bearish cases on PFE line up.

The bullish case

  • Wall Street's consensus price target of $28.50 implies +3.1% upside from $27.64.
  • The Street's most bullish target is $31.00 (+12.2%).
  • Positive 0.6% session move.
  • Positive price momentum.
  • Pfizer Inc. (PFE) moved +1.73% from $26.59 to $27.05 on 2026-08-10, reaching a new 30-day high.

The bearish case

  • The most bearish analyst target is $26.00 (-5.9%).
  • 1 analyst downgrade in the past 90 days, most recently HSBC to Hold (2026-07-06).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Sep 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $29+3.1%
= 7 maintains1 downgrades
HSBC maintained Hold · 2026-09-10
SEC filings watch
8-K2026-08-04
Material event — review for impact
high
10-Q2026-08-04
Quarterly financial results
medium
8-K2026-06-18
Material event — review for impact
high
8-K2026-06-18
Material event — review for impact
high
Peer context
PFE+0.6%
LLY+1.3%
UNH-0.0%
JNJ+1.1%
ABBV+0.6%
MRK+1.6%

Previous notable changes for PFE

Valuation2026-08-31+1.8%via Yahoo Finance
Pfizer rose 2.34% to $28.61, driven by sector-wide optimism in oncology and vaccine pipelines alongside positive peer trial results for mRNA cancer treatments (Merck, Moderna). The gain reflects momentum in PFE's own oncology portfolio, particularly Padcev revenue growth in Q2 2026, plus progress on pipeline milestones including Lyme disease and updated COVID-19 vaccine candidates. Volume of 23.5M shares ran at 0.72x the time-adjusted average—normal for this point in the session.
Activity2026-08-25+2.1%via Yahoo Finance
Pfizer shares rose 2.00% to $28.53, driven by positive investor sentiment following recent domestic drug pricing agreements and broader pharmaceutical sector momentum around clinical progress, according to web sources. Volume of 9.88M shares ran at 0.80x typical pace 120 minutes into the session.
Valuation2026-08-21+1.0%via MarketWatch
Pfizer rose 2.21% to $28.41 as positive Phase 3 clinical trial results from industry peers Merck and Moderna for an mRNA cancer treatment boosted sector sentiment and investor enthusiasm across pharmaceutical stocks with oncology and mRNA exposure, per web sources including MarketWatch and Yahoo Finance. Volume stood at 10.9M shares (1.20x normal for this time of day).
Activity2026-08-19+3.6%via Seeking Alpha
Pfizer rose 3.69% to $28.25 on elevated volume (2.36x average for the time of day), though no specific intraday catalyst was identified in available sources. The stock remains near intrinsic value according to recent analysis from Seeking Alpha, which rates it a cautious Buy despite headwinds from a looming patent cliff and stretched balance sheet.
Upcoming catalysts & outlook
Next earnings
2026-11-03 (est.)
in 46 days
Thesis shift
Neutral / Mixed
bullish signal
Risk level
Low
from change events

Frequently asked questions about PFE

Why did Pfizer Inc. (PFE) stock move?

PFE rose 0.6% to $27.64. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.

How much did PFE stock rise?

PFE gained 0.64% ($0.18) versus the prior close of $27.46, last trading at $27.64 on 0.7× average volume.

When is Pfizer Inc.'s next earnings date?

PFE's next earnings report is estimated for 2026-11-03 — about 46 days away.

What is the analyst price target for PFE?

The consensus analyst price target for PFE is $28.50, about 3.1% above the current $27.64. Over the past 90 days, analysts recorded 0 upgrades, 7 maintains, and 1 downgrade.

Is the PFE move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median +1.1% against PFE's +0.6%. PFE ranks top 5 of 7 peers.

How BestStocks tracks PFE

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared PFE-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for PFE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 18, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.